Alembic Pharmaceuticals Limited (BOM:533573)
India · Delayed Price · Currency is INR 768.85
-19.95 (-2.53%)
At close: Feb 13, 2026
Alembic Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 72,668 | 66,721 | 62,286 | 56,526 | 53,058 | 53,931 |
Other Revenue | -0.1 | -0.1 | - | - | - | - |
Revenue | 72,668 | 66,721 | 62,286 | 56,526 | 53,058 | 53,931 |
Revenue Growth (YoY) | 13.20% | 7.12% | 10.19% | 6.54% | -1.62% | 17.10% |
Cost of Revenue | 20,703 | 18,808 | 17,961 | 17,748 | 14,982 | 13,402 |
Gross Profit | 51,965 | 47,913 | 44,325 | 38,778 | 38,076 | 40,529 |
Selling, General & Admin | 16,866 | 15,623 | 14,463 | 11,691 | 11,330 | 10,512 |
Other Operating Expenses | 23,420 | 22,153 | 20,500 | 19,892 | 17,951 | 15,213 |
Operating Expenses | 43,328 | 40,615 | 37,718 | 34,401 | 32,201 | 27,561 |
Operating Income | 8,636 | 7,298 | 6,607 | 4,378 | 5,875 | 12,968 |
Interest Expense | -955.9 | -787.7 | -561.9 | -501.7 | -177.3 | -160.2 |
Interest & Investment Income | 59.6 | 59.6 | 21 | 3.3 | 17.3 | 15.8 |
Earnings From Equity Investments | -15.3 | 8.7 | -9.8 | -309.2 | 52.8 | 317.4 |
Currency Exchange Gain (Loss) | 233.9 | 233.9 | 176.9 | -0.9 | 443.1 | 772.8 |
Other Non Operating Income (Expenses) | 84 | 78.3 | 3.9 | 2.4 | 0.5 | 1.7 |
EBT Excluding Unusual Items | 8,043 | 6,891 | 6,238 | 3,572 | 6,211 | 13,916 |
Gain (Loss) on Sale of Investments | 14.7 | 14.7 | 43.9 | 7.5 | 28.7 | 62.8 |
Gain (Loss) on Sale of Assets | 32.6 | 32.6 | 17 | -47 | 5.4 | 13.9 |
Other Unusual Items | -422.3 | 128.7 | - | - | - | - |
Pretax Income | 7,673 | 7,072 | 6,318 | 3,546 | 6,254 | 13,998 |
Income Tax Expense | 1,413 | 1,252 | 160 | 126.1 | 1,045 | 2,533 |
Earnings From Continuing Operations | 6,259 | 5,820 | 6,158 | 3,420 | 5,209 | 11,465 |
Minority Interest in Earnings | 30.3 | 14.1 | - | - | - | - |
Net Income | 6,290 | 5,834 | 6,158 | 3,420 | 5,209 | 11,465 |
Net Income to Common | 6,290 | 5,834 | 6,158 | 3,420 | 5,209 | 11,465 |
Net Income Growth | 4.00% | -5.26% | 80.07% | -34.35% | -54.56% | 38.33% |
Shares Outstanding (Basic) | 196 | 197 | 197 | 197 | 197 | 194 |
Shares Outstanding (Diluted) | 196 | 197 | 197 | 197 | 197 | 194 |
Shares Change (YoY) | -0.41% | - | - | - | 1.46% | 2.77% |
EPS (Basic) | 32.07 | 29.68 | 31.33 | 17.40 | 26.50 | 59.18 |
EPS (Diluted) | 32.07 | 29.68 | 31.33 | 17.40 | 26.50 | 59.18 |
EPS Growth | 4.44% | -5.26% | 80.07% | -34.35% | -55.22% | 34.60% |
Free Cash Flow | - | -4,757 | 4,757 | 2,805 | 1,267 | 8,039 |
Free Cash Flow Per Share | - | -24.20 | 24.20 | 14.27 | 6.45 | 41.49 |
Dividend Per Share | - | 11.000 | 11.000 | 8.000 | 10.000 | 14.000 |
Dividend Growth | - | - | 37.50% | -20.00% | -28.57% | 100.00% |
Gross Margin | 71.51% | 71.81% | 71.16% | 68.60% | 71.76% | 75.15% |
Operating Margin | 11.88% | 10.94% | 10.61% | 7.75% | 11.07% | 24.05% |
Profit Margin | 8.65% | 8.74% | 9.89% | 6.05% | 9.82% | 21.26% |
Free Cash Flow Margin | - | -7.13% | 7.64% | 4.96% | 2.39% | 14.90% |
EBITDA | 11,274 | 9,891 | 9,141 | 6,962 | 8,585 | 14,663 |
EBITDA Margin | 15.52% | 14.82% | 14.67% | 12.32% | 16.18% | 27.19% |
D&A For EBITDA | 2,638 | 2,593 | 2,533 | 2,584 | 2,710 | 1,695 |
EBIT | 8,636 | 7,298 | 6,607 | 4,378 | 5,875 | 12,968 |
EBIT Margin | 11.88% | 10.94% | 10.61% | 7.75% | 11.07% | 24.05% |
Effective Tax Rate | 18.42% | 17.70% | 2.53% | 3.56% | 16.70% | 18.10% |
Revenue as Reported | 73,099 | 67,146 | 62,569 | 56,554 | 53,563 | 54,804 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.